Established in 1947, Bupa's purpose is helping people live longer, healthier, happier lives and making a better world. We are an international healthcare company serving over 60 million customers worldwide. With no shareholders, we reinvest profits into providing more and better healthcare for the benefit of current and future customers. Bupa has businesses around the world, principally in Australia, the UK, Spain, Poland, Chile, Hong Kong SAR, India, Türkiye, Brazil, Mexico and New Zealand. We also have associate businesses11 in Saudi Arabia. For more information, visit www.bupa.com

Leveraging the latest advances in medicine, behavioral science, and technology, Workit Health makes recovery from substance use more accessible and achievable for all, with a success rate that is double that of traditional methods. Workit is the leading provider of telemedicine SUD and behavioral health treatment in the U.S., partnering with health plans to expand access to the gold-standard of care for over 110 million lives. With simple online scheduling, virtual visits, and medication e-prescribed to a local pharmacy, Workit Health makes it simple for people to receive whole-person care for substance use and mental health conditions. Workit members receive treatment for over 30 commonly co-occurring conditions from their dedicated clinician, at one-tenth of the cost of traditional care. Workit Health is a B-corporation dedicated to making a positive social impact, is accredited by the Joint Commission, and has partnered with the National Science Foundation and National Institute on Drug Abuse. The company is headquartered in Michigan, with over 250 employees nationwide. Learn more at workithealth.com.

Wellington Partners is one of the most successful pan-European venture capital firms. With funds totalling over € 800 million, we have invested throughout Europe in companies that have the potential to become real market leaders for more than 15 years. We are committed to providing outstanding entrepreneurs with the necessary resources to fund their strategies. We typically lead financing rounds ranging from € 0.5 million to € 20 million. Depending on the maturity of the company, our own commitment can go as high as € 15 million. Providing funding is only one part of our business. After funding, the entrepreneurs we back have access to the advice and guidance of our complete team and our entire global network. Our investment professionals operate out of four offices, located in London, Munich, Zurich and Palo Alto. The pan-European and transatlantic makeup of our organisation enables us to support our portfolio in expanding globally. To date, Wellington Partners has invested in more than 100 companies throughout Europe. We have been a part of great successes as well as dismal failures. In our view, success has always been the result of a great idea executed by a great team with strong leadership and commitment; plus an enormous amount of hard work and an ounce of luck, the good fortune to be in the right place at right time.

Nina Capital is a specialized venture capital firm investing in healthcare transformation powered by information technology led by need-driven founders.

Our Future Health is the UK’s largest ever health research programme, bringing people together to develop new ways to prevent, detect and treat diseases. Our mission is to create an incredibly detailed picture of the UK population’s health, by recruiting up to five million adult volunteers from across the UK. Each volunteer will be asked to fill out a questionnaire and provide a blood sample that can be linked to their health records. Taken together, the data will present health researchers with a powerful tool to identify new ways of tackling diseases such as cancer, diabetes, and dementia. It's an unprecedented challenge that involves answering questions that have never been asked before – ethical, practical, and technological. And by getting these answers right, we believe Our Future Health will allow future generations to live in good health for longer. We are currently expanding our team and looking for specialists across various fields – people who are motivated by the opportunity of creating something new that will make a difference to society. Click on the Jobs tab above to start exploring our current opportunities. Our Future Health is a registered charity in England, Wales and Scotland.

Investing in companies that, through science and technology, cultivate joy to improve the way we live.

Calm/Storm is an exclusive founder network and boutique venture capital firm. We focus on talents, not industries. We believe in lifelong learning & personal growth, empowering entrepreneurs with unique access to successful founders. We are a fund built by founders for founders.

Technology has fundamentally changed the way we engage with the world and each other — both in business and in life. FINN Partners is one of the top technology PR companies with a global team of talented experts. From innovative startups to industry giants, we use our deep expertise and understanding of technology trends to help clients transform their brands through strategic, data-driven communications programmes. To learn more about how we can help you achieve your communications goals, please don’t hesitate to get in touch: techlondon@finnpartners.com

G4A is Bayer’s digital health partnerships and investments team dedicated to scaling digital health companies in order to create impact and change the experience of health. Our team’s vision is to reach health for all through digital health. To attain this goal we are working together with like-minded start-ups, digital health companies, government, investors, and strategic partners to offer early stage start-up investments as well as commercial partnerships and late stage investments.

Chronomics is a tech-bio company on a mission to make biology accessible and actionable to everyone. The world is at the dawn of a ‘bio-revolution’ - with science set to transform our lives in the coming decades. And yet today, accessing biological information - and making it actionable - is complex, costly and cumbersome. The revolution needs an engine - and we are building it. We design and deploy ‘bio-infrastructure’ across more than a dozen verticals to simplify, speed-up and scale the use of biomarkers to improve everyday decisions. From tele-health to travel; sleep to skincare; multivitamins to managing menopause - and many others - we partner with the world’s largest and most impactful organizations, using science to transform how they diagnose, personalize and evaluate their offerings. Co-located between the US and Europe, we’re a team that spans science, technology, supply chain, operations, commercial - and we’re growing. Rapidly.

The American Medical Association is the premier national organization providing timely, essential resources to empower physicians, residents and medical students to succeed at every phase of their medical lives. Physicians have entrusted the AMA to advance the art and science of medicine and the betterment of public health on behalf of patients for more than 170 years. For more information, visit ama-assn.org. For commenting policies, see our Code of Conduct: http://bit.ly/1aEMHr2

PicturaBio develops rapid pathogen detection systems that combine single-molecule fluorescence imaging with machine learning analysis. The platform acquires digital images of labeled biomolecules and classifies infectious agents in near real time. Proprietary hardware features a dedicated imager and single-use cartridges for point-of-care testing. Software pipelines analyze image data to deliver identification results and support diagnostic workflows. Offerings include instrumentation, consumables, and analytic software for imaging-based infectious disease testing. Funding awards, including support from DASA, back development of AI-driven assays and validation studies.

Beyond Sustainability, Business Resilience. We believe that the most resilient businesses in the future will be the ones that have the lowest negative impact on the planet and the highest contribution to society while making a difference for their customers. Therefore, we help companies to set up resilient strategies and transform their business model based on sustainable development, collective intelligence, and value innovation tools: Lower impact, better meaning, and higher value, this is what we aim for. Think Green Think People Think Innovation Think Next.

ERGO is one of the major insurance groups in Germany and Europe. The Group is represented in over 20 countries worldwide, with a focus on Europe and Asia. ERGO offers its retail and corporate customers a broad product portfolio in all the main clas-ses of insurance as well as comprehensive assistance and other services. Three units operate under the umbrella of ERGO Group AG: ERGO Deutschland AG, ERGO International AG and ERGO Technology & Services Management AG. The German and international businesses as well as the global management of IT and technology services are organized in these units. About 38,700 people work either as salaried employees or as full-time self-employed sales representatives for the Group. In the 2023 financial year, ERGO generated insurance revenue of 20.1 billion euros and a net result of 721 million euros. ERGO is part of Munich Re, one of the world's leading reinsurers and risk carriers. More at www.ergo.com. Imprint: www.ergo.com/en/Anbieter

Over the past decade we have transformed into a focused leader in health technology. At Philips, our purpose is to improve people’s health and well-being through meaningful innovation. We aim to improve 2.5 billion lives per year by 2030, including 400 million in underserved communities. We see healthcare as a connected whole. Helping people to live healthily and prevent disease. Giving clinicians the tools they need to make a precision diagnosis and deliver personalized treatment. Aiding the patient's recovery at home in the community. All supported by a seamless flow of data. As a technology company, we – and our brand licensees – innovate for people with one consistent belief: there’s always a way to make life better. Visit our website: http://www.philips.com/ Follow our social media house rules https://www.philips.com/a-w/about-philips/social-media.html

Light IT Global is a Data Science company that provides custom web and mobile software development services that include, IT consulting, design, market research, quality assurance, post-release assistance, and many other solutions worldwide. Even though we began our way as a software development team, over the years of providing solutions we have evolved into a Data Science company that specialises in Big Data, Data Mining & Processing, Artificial Intelligence, Deep Learning, Business Intelligence, and many other tech fields that change the present and the future. The variety of industries we've already covered with our software solutions includes: - Fintech, - Healthcare, - Energy, - Retail, - Travel, - Entertainment, - Media and Advertising, - Education, etc. Our team has specialists with different experience and set of skills, as well as our best Light Academy graduates. Nevertheless, our clients never get mistakes made by newbie front-end and back-end developers because all projects are under strict and constant control of our Tech Leads.

Bayer is a global enterprise with core competencies in the life science fields of healthcare and nutrition. We design our products and services to serve the most essential human needs of health and nutrition. At the same time, we strive to address some of the world’s biggest challenges presented by a growing and aging global population. At Bayer, we’re committed to driving sustainable development and generate a positive impact with our businesses. Through the power of science, we’re pioneering new possibilities that advance life for all of us. That means reimagining how we care for ourselves and one another by empowering everyday health, improving approaches to patient care, and finding better ways to nourish our communities around the world. Data Privacy Statement & Imprint: https://www.bayer.com/en/glob-li-bayer-en-dps-imprint

We’re the power behind the forward-thinkers, future-makers and leap-takers. We partner with innovators and investors in the UK, US, Israel, Hong Kong, Europe, Australia & New Zealand, helping them ignite the bold ideas that reshape our world. We offer flexible banking solutions for start-ups, scale-ups, growth businesses, investors and those working towards IPO. Whether it’s comprehensive banking, managing cashflow, plans for buyouts or Global Funds Banking, we power ideas at every stage of their journey. From the first-time founders to the funds that back them and everything in between. Here’s to never standing still. We're proud to accelerate growth for tech and life science businesses, create meaningful connections and open a world of global opportunity for entrepreneurs and investors alike.

Hay algo que me afecta y empeora mi calidad de vida, que no es visible y que no se entiende. Somos la Fundación Visible, los que vemos la letra pequeña, los que vemos lo que esconde el asterisco. Somos los que nos comprometemos en Hacer Visible Lo Invisible para darle la importancia que se merece. Somos los proyectos que ayudan a hacer visible lo que (casi) nadie ve. #MIGRAÑA #COVIDPERSISTENTE #ENFERMEDADCRÓNICA #HEALTH #SALUD #ENDOMETRIOSIS #FATIGACRONICA #SALUDMENTAL #PACIENTE #VOZDELPACIENTE #EXPERIENCIAPACIENTE

Verdane is a specialist growth buyout investment firm that partners with tech-enabled and sustainable businesses that help to digitalise and decarbonise the European economy. Verdane funds have the most flexible mandates in the industry. The firm can invest as a minority or majority investor, replacement or growth capital, in single companies or in portfolios of companies. Verdane has over €8 billion in assets under management and its funds have made more than 200 investments in fast-growing businesses since 2003. Verdane’s team of over 150 investment professionals and operating experts is based out of Berlin, Munich, Copenhagen, Helsinki, London, Oslo and Stockholm, and combines deep sector expertise with deep local networks and presence in core European markets. Verdane is also a certified B Corporation, the most ambitious sustainability accreditation globally. The firm only backs businesses that pass its 2040 test, which indicates whether the company can thrive in a more sustainable future economy. Verdane is partly owned by the Verdane Foundation, which is focused on two areas: climate change and more equitable and inclusive local communities. Further information: www.verdane.com

Launched in 2006, Amazon Web Services (AWS) began exposing key infrastructure services to businesses in the form of web services -- now widely known as cloud computing. The ultimate benefit of cloud computing, and AWS, is the ability to leverage a new business model and turn capital infrastructure expenses into variable costs. Businesses no longer need to plan and procure servers and other IT resources weeks or months in advance. Using AWS, businesses can take advantage of Amazon's expertise and economies of scale to access resources when their business needs them, delivering results faster and at a lower cost. Today, Amazon Web Services provides a highly reliable, scalable, low-cost infrastructure platform in the cloud that powers hundreds of thousands of businesses in 190 countries around the world. With data center locations in the U.S., Europe, Singapore, and Japan, customers across all industries are taking advantage of our low cost, elastic, open and flexible, secure platform.

As one of the largest global insurers, our purpose is to act for human progress by protecting what matters. Protection has always been at the core of our business, helping individuals, businesses and societies to thrive. And AXA has always been a leader, an innovator, an entrepreneurial company, fostering progress in all its dimensions. Our purpose also links back to the Group's roots. From the outset, AXA has been committed to acting as a force for collective good. From solidarity-based actions with AXA Hearts In Action to work on prevention issues with the AXA Research Fund and the fight against climate change, AXA has always been attentive to its social environment and embraced its responsibility as an insurer: responsibility for taking action upstream in order to better understand risks, with one goal in mind: to ensure better protection. Discover more: https://www.axa.com/en/about-us/our-purpose To know more about AXA's Privacy Policy - https://www-axa-com.cdn.axa-contento-118412.eu/www-axa-com/1cd44dfb-3b7a-4cf7-933b-06024cf7f25b_axa_privacypolicy_internetusers_va.pdf

Karista is an early-growth investment firm backing ambitious entrepreneurs across Europe. For nearly 25 years, we have supported over 100 startups and scale-ups, many of which have achieved successful exits through acquisitions or listings on major exchanges, including Nasdaq. Our current strategy focuses on two key sectors: HealthTech and Space, Defence & Security, executed through dedicated funds and specialized teams with deep domain expertise. We primarily invest in early-growth opportunities, while selectively supporting early-stage moonshot projects with transformative potential. Trusted by leading institutional investors, financial groups, strategic corporates, and family offices, Karista pairs capital with hands-on support and strategic guidance. We leverage our extensive networks and sector expertise to help founders scale rapidly, execute their global commercial strategy, innovate boldly, and achieve transformative, market-leading success.

Founded to serve health 70 years ago, Servier is a global pharmaceutical group governed by a non-profit Foundation that aspires to make a meaningful social impact for patients and for a sustainable world. The Group’s unique governance model preserves its independence and means it can fully serve its vocation of being committed to therapeutic progress to serve patient needs while adopting a long-term vision. Its employees are fully committed to this shared vocation, which serves as a source of inspiration every day. A world leader in cardiometabolism and venous diseases, Servier has made a major shift into oncology, which represents a new pillar of strategic growth. The Group devotes close to 70% of its R&D budget to this field, with the ambition of becoming a focused and innovative player in the development of treatments targeting rare cancers. Neurology will constitute a future growth driver. Servier is focusing on a limited number of diseases in this area where accurate patient profiling makes it possible to offer a targeted therapeutic response through precision medicine. To promote widespread access to quality care at a lower cost, the Group also offers a range of quality generic drugs covering most pathologies, leveraging well-known brands in France, Eastern Europe and Brazil. In all these areas, the Group takes patient considerations into account at every stage of the medicine life cycle. Headquartered in France, Servier relies on committed teams and strong geographical footprint; its medicines are available in close to 140 countries. In 2023/2024, the Group achieved sales revenue of €5.9 billion and EBITDA of €1.3 billion in 2024 (22.2%). Today, the Group employs over 22,000 people worldwide. -- To report a suspected adverse event with a Servier drug, please visit servier.com

Bridging the gap between disruptive discovery products and real-world patient reach, we identify high-potential compounds for in-licensing, we conduct clinical development and then select large pharmaceutical commercialization partners for out-licensing to maximize patient access across the globe. Through this specialized business model, Debiopharm can focus on the development of prescription drugs that target unmet medical needs in oncology and bacterial infections. Debiopharm completed the development and has licensed out 2 compounds: - Triptorelin, the active substance of Decapeptyl®/Trelstar®/Pamorelin®/Triptodur® 1, 3 and 6-month formulation and Moapar®/Salcacyl® -Oxaliplatin, the active substance of the branded Eloxatin®/Elplat®/Dacotin®/Dacplat® If your university or biotech start-up has interesting molecules in early-stage research and you’re seeking a competent and committed partner to develop them further, please contact us!